Renal cell carcinoma (advanced) - evaluation report
01a - Final updated post-appeal Scope
01b- Final updated post-appeal Matrix of Consultees and Commentators
02- Post-appeal Manufacturer/sponsor addendum submission- Pfizer
03a - NICE request to the manufacturer for clarification
on their submission
03b- Manufacturer clarification response
04a- Post-appeal patient group submission- James Whale Fund for Kidney Cancer
04b- Post-appeal patient group submission- Kidney Cancer Support Network
05a- Post-appeal Patient expert personal perspective- Hanlon
05b- Post-appeal Clinical expert personal perspective-Hawkins
06- Post-appeal Evidence Review Group report addendum factual accuracy check prepared by
Kleijnen Systematic Reviews
07-Post-appeal Erratum to the Evidence Review Group report addendum prepared by Kleijnen Systematic Reviews
08-Post-appeal Grunwald abstract summary prepared by Pfizer
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Renal cell carcinoma (advanced) - evaluation report
04 March 2014 (2.84 Mb 6 sec) |
This page was last updated: 03 March 2014